Evidence map›Paper›PMID 34748628›Full record

ArticleBlood2021

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.

Simona Pagliuca, Carmelo Gurnari, Hassan Awada, Ashwin Kishtagari, Sunisa Kongkiatkamon, Laila Terkawi, Misam Zawit, Yihong Guan, Thomas LaFramboise, Babal K Jha and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. HLA-DQB1*03:01 and risk of HBV-related HCC.Hepatology (Baltimore, Md.) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 5 countries.

Simona PagliucaTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-4688-2478
Carmelo GurnariTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-6829-5544
Hassan AwadaTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Ashwin KishtagariTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Sunisa KongkiatkamonTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Laila TerkawiTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Misam ZawitTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-2991-4386
Yihong GuanTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-8002-5141
Thomas LaFramboiseDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH.
Babal K JhaTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-7660-5255
Bhumika J PatelLeukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.
Betty K HamiltonBlood and Marrow Transplant Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.
Navneet S MajhailBlood and Marrow Transplant Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-7082-891X
Sofie LundgrenHematology Research Unit Helsinki, University of Helsinki-Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.ORCID 0000-0003-3146-9816
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki-Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.ORCID 0000-0002-0816-8241
Yogen SaunthararajahTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-9757-1031
Valeria VisconteTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH.
Chao-Yie YangDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN.ORCID 0000-0002-5445-0109
Tobias L LenzResearch Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany; and.
Jaroslaw P MaciejewskiTranslational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic · USUniversity of Helsinki · FICase Western Reserve University · USUniversität Hamburg · DEUniversity of Rome Tor Vergata · ITUniversity of Tennessee Health Science Center · US

Funding

TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0M
Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
Novel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4M
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1M
Investigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9M
The Role of Somatic Mutations in Aplastic AnemiaR01HL128425 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2015 to 2016
$793k
Integrating Clues from the Somatic Genome in the Search for Rare Germline Cancer Susceptibility VariantsR21CA249138 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LAFRAMBOISE, THOMAS LOUIS · 2020 to 2021
$414k
NCI NIH HHS R21 CA249138NCI NIH HHS R35 CA232097NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL128425NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

Idiopathic aplastic anemia (IAA) is a rare autoimmune bone marrow failure (BMF) disorder initiated by a human leukocyte antigen (HLA)-restricted T-cell response to unknown antigens. As in other autoimmune disorders, the predilection for certain HLA profiles seems to represent an etiologic factor; however, the structure-function patterns involved in the self-presentation in this disease remain unclear. Herein, we analyzed the molecular landscape of HLA complexes of a cohort of 300 IAA patients and almost 3000 healthy and disease controls by deeply dissecting their genotypic configurations, functional divergence, self-antigen binding capabilities, and T-cell receptor (TCR) repertoire specificities. Specifically, analysis of the evolutionary divergence of HLA genotypes (HED) showed that IAA patients carried class II HLA molecules whose antigen-binding sites were characterized by a high level of structural homology, only partially explained by specific risk allele profiles. This pattern implies reduced HLA binding capabilities, confirmed by binding analysis of hematopoietic stem cell (HSC)-derived self-peptides. IAA phenotype was associated with the enrichment in a few amino acids at specific positions within the peptide-binding groove of DRB1 molecules, affecting the interface HLA-antigen-TCR β and potentially constituting the basis of T-cell dysfunction and autoreactivity. When analyzing associations with clinical outcomes, low HED was associated with risk of malignant progression and worse survival, underlying reduced tumor surveillance in clearing potential neoantigens derived from mechanisms of clonal hematopoiesis. Our data shed light on the immunogenetic risk associated with IAA etiology and clonal evolution and on general pathophysiological mechanisms potentially involved in other autoimmune disorders.

Indexed as

Genes, MHC Class IIAdultAllelesAnemia, AplasticCohort StudiesFemaleGenotypeHLA-D AntigensHumansMaleMiddle AgedHLA-D Antigens

Identifiers

PMID34748628
PMCPMC8718627
OpenAlexW3212450612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.